Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.

An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Balancing the benefits and risks of rebalancing coagulation in haemophilia.

Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.

Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.

Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial.

An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Balancing the benefits and risks of rebalancing coagulation in haemophilia.

Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.

Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.